+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients



A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients



Transplantation 97(4): 470-473



The treatment of steroid-resistant rejection (SRR) is associated with severe recurrent hepatitis C virus (HCV) infection after liver transplantation (LTx). After OKT3 was recently withdrawn from the market, thymoglobulin (TG) became the principal treatment for SRR. A retrospective analysis of 32 HCV patients who were treated for SRR with OKT3 (n=15) or TG (n=17) using yearly protocol liver biopsies. Mean follow-up was 4.3 years (OKT3) and 3.2 years (TG). We compared both groups for patient survival, graft loss, and severity of HCV recurrence, manifested as the mean stage of fibrosis (MSF). Patient survival at 1, 2, and 5 years after LTx was 80%, 73%, and 67% in the OKT3 group and 82%, 77%, and 64% in the TG group, respectively. At 2 years after LTx, the graft losses were 3 versus 4 in the OKT3 and TG groups, respectively. At years 1 and 2, the MSF in the OKT3 group was 1.9 and 2.3 versus 2.4 and 2.8 in the TG group, respectively. None of the differences between both groups was statistically significant. There was no significant difference in patient survival, graft loss, or severity of recurrent HCV, measured as MSF, between both groups.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051111800

Download citation: RISBibTeXText

PMID: 24142032

DOI: 10.1097/01.tp.0000435701.54019.98


Related references

OKT3 treatment of steroid-resistant rejection in pediatric liver transplant recipients. Journal of Pediatric Gastroenterology and Nutrition 14(1): 86-91, 1992

Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplantation Proceedings 28(2): 1014, 1996

Antithymocyte globulin for steroid resistant rejection in renal transplant recipients immunosuppressed with triple therapy. Transplant International 2(1): 27-32, 1989

Use of antithymocyte globulin and cyclosporine to treat steroid-resistant rejection episodes in renal transplant recipients. Transplantation Proceedings 19(1 Pt 3): 1889-1891, 1987

Reversal of steroid- and antithymocyte globulin-resistant acute rejection crises in renal transplantation with monoclonal antibody (OKT3). Transplantation Proceedings 22(4): 1753-1754, 1990

FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. Transplantation Proceedings 28(6): 3166-3168, 1996

Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. Transplantation Proceedings 29(7): 2955-2957, 1997

OKT3 monoclonal antibody treatment of steroid-resistant liver transplant rejection. Current Therapeutic Research. 55(4): 382-395, 1994

FK 506 is as effective as OKT3 for initial treatment for steroid resistant rejection in liver transplant patients. Hepatology 22(4 PART 2): 143A, 1995

Cyclosporine and okt 3 salvage for steroid resistant and antithymocyte globulin resistant renal transplant rejection. Transplantation Proceedings 17(6): 2748-2750, 1985

Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation. Transplant International 9(6): 570-575, 1996

Antilymphoblast globulin treatment of steroid-resistant rejection in cyclosporine-immunosuppressed renal transplant recipients. Transplantation Proceedings 19(1 Pt 3): 1892, 1987

Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol. Journal of Cardiovascular Surgery 34(2): 135-140, 1993

A prospective comparison of murine monoclonal cd 3 okt3 antibody based and equine antithymocyte globulin based rejection prophylaxis in cardiac transplantation decreased rejection and less corticosteroid use with okt3. Transplantation 47(4): 599-605, 1989

Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplantation Proceedings 38(5): 1307-1313, 2006